(L-R) Dr Santosh Mishra, Mr Samarth Jain, CEO, Positive Bioscience, Dr Gowhar Shafi & Mr Shantanu Parihar launched Positive Select
Positive Bioscience announced the launch of its next generation product, Positive Select, a RNA sequencing test for Cancer treatment. Positive Select is the latest arsenal in fighting against cancer and is intended to aid Oncologists select the best treatment for cancer patients. Positive Select is based on whole RNA sequencing which is the latest technology available in the world and enhances the utility of comprehensive genomics profile manifold bringing Genomics test closer to clinical practice. With this Positive Bioscience becomes the first company in India to offer whole RNA sequencing test commercially for cancer.
"By launching Positive Select, Positive Bioscience is again demonstrating its commitment to innovation and making cutting edge molecular information available to oncology community in India and worldwide," said Mr Samarth Jain, chief executive officer, Positive Bioscience. He added, "Cancer is driven by genomic alterations. Positive Select detects genomic alterations in all 25,000 genes and recommends treatment options with best probability of response as compared to recommendations based on testing of 4-5 genes through conventional testing. We expect that Positive Select will revolutionize molecular diagnostics in a way CT scan revolutionized imaging diagnostics when X Ray was a norm."
"In this era of Precision Oncology, RNA sequencing is a recent advancement in diagnostic technology, offering the most comprehensive genetic information on various alterations and the level of expression on thousands of genes in a single step. The information can be used to select the best treatment option with least side effects," said Dr Amit Verma, consultant - molecular oncology and cancer genetics, Max Super Speciality Hospitals Saket, New Delhi.
Positive Select is a comprehensive genomic solution for solid tumours(Lung Cancer, breast Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma etc) as well as Haematological cancers(leukaemia, lymphoma, myeloma) designed to provide oncologists with clinically actionable report which can identify the molecular alterations in a patient's tumour and match those alterations with relevant targeted therapies and clinical trials.
The test employs RNA sequencing to detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.